Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
IMNMBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST. Interested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome’s website at www.immunome.com. A replay webcast will b
Immunome Announces Pricing of Public Offering of Common Stock
IMNMBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 18,625,000 shares of its common stock at a price to the public of $21.50 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and other offe
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMNM(NASDAQ:IMNM) BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Sept. 2, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 117,000 shares of common stock to 8 new employees under the Company’s 2024 Inducemen
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
IMNM(NASDAQ:IMNM) BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, Sept. 9, 2025 at 1:00 p.m. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
IMNMBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2025 and provided a business update. “Immunome made substantial progress in the second quarter of 2025, underscored by the continued advancement of our clinical programs towards key milestones,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of
Immunome Q1 EPS $(0.52) Beats $(0.68) Estimate, Sales $2.93M Beat $285.71K Estimate
IMNMLake Street Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $23
IMNMWedbush Reiterates Outperform on Immunome, Maintains $33 Price Target
IMNMStephens & Co. Reiterates Overweight on Immunome, Maintains $30 Price Target
IMNMGuggenheim Maintains Buy on Immunome, Lowers Price Target to $25
IMNMImmunome FY 2024 GAAP EPS $(5.00) Misses $(4.38) Estimate
IMNMLifeSci Capital Initiates Coverage On Immunome with Outperform Rating, Announces Price Target of $20
IMNMImmunome Doses First Patient in Trial for New Cancer-Fighting Drug IM-1021
IMNMImunon Announces Phase 1 Trial Results For IMNN-101 DNA Vaccine Showing 2-4x Antibody Increase Vs. Omicron Variant With No Serious Adverse Effects In 24 Participants; Vaccine Demonstrated Cross-Reactivity With New Variants
IMNMPiper Sandler Maintains Overweight on Immunome, Lowers Price Target to $21
IMNMImmunome Form 4 Filing Shows President And CEO Clay B Siegall Bought 100,000 Shares Of Stock At A Price Of $13.88/Share
IMNMImmunome Promotes Max Rosett To CFO, Effective May 9
IMNM